Rep. Robert Bresnahan, Jr. Sells CVS Health Co. (NYSE:CVS) Stock

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of CVS Health Co. NYSE: CVS. In a filing disclosed on May 31st, the Representative disclosed that they had sold between $1,001 and $15,000 in CVS Health stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zimmer Biomet NYSE: ZBH on 5/15/2025.
• Sold $15,001 - $50,000 in shares of Elevance Health NYSE: ELV on 5/15/2025.
• Sold $15,001 - $50,000 in shares of PepsiCo NASDAQ: PEP on 5/15/2025.
• Sold $1,001 - $15,000 in shares of WEC Energy Group NYSE: WEC on 5/15/2025.
• Purchased $15,001 - $50,000 in shares of Advanced Micro Devices NASDAQ: AMD on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Hershey NYSE: HSY on 5/15/2025.
• Purchased $1,001 - $15,000 in shares of Kraft Heinz NASDAQ: KHC on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Exxon Mobil NYSE: XOM on 5/15/2025.
• Sold $1,001 - $15,000 in shares of Danaher NYSE: DHR on 5/15/2025.
• Sold $1,001 - $15,000 in shares of International Flavors & Fragrances NYSE: IFF on 5/15/2025.

CVS Health Price Performance

CVS stock traded down $0.03 during midday trading on Wednesday, hitting $63.56. 5,852,349 shares of the stock were exchanged, compared to its average volume of 11,131,532. The stock has a market cap of $80.40 billion, a price-to-earnings ratio of 17.37, a PEG ratio of 0.98 and a beta of 0.60. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $72.51. The stock's 50-day moving average price is $65.47 and its 200-day moving average price is $59.77. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS - Get Free Report) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. The firm had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the prior year, the business posted $1.31 earnings per share. The firm's revenue for the quarter was up 7.0% compared to the same quarter last year. Research analysts predict that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Tuesday, April 22nd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 4.19%. The ex-dividend date was Tuesday, April 22nd. CVS Health's dividend payout ratio is presently 63.48%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bell Investment Advisors Inc lifted its stake in shares of CVS Health by 119.8% in the 1st quarter. Bell Investment Advisors Inc now owns 455 shares of the pharmacy operator's stock valued at $31,000 after acquiring an additional 248 shares during the last quarter. Saudi Central Bank purchased a new stake in CVS Health in the first quarter worth $34,000. Costello Asset Management INC raised its holdings in CVS Health by 281.3% in the first quarter. Costello Asset Management INC now owns 572 shares of the pharmacy operator's stock worth $39,000 after purchasing an additional 422 shares in the last quarter. Stone House Investment Management LLC bought a new stake in shares of CVS Health during the 1st quarter valued at $39,000. Finally, Stonebridge Financial Group LLC purchased a new stake in shares of CVS Health in the 4th quarter worth about $28,000. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on CVS. Cowen reaffirmed a "buy" rating on shares of CVS Health in a report on Monday, May 5th. Cantor Fitzgerald raised shares of CVS Health from a "neutral" rating to an "overweight" rating in a research report on Wednesday, February 12th. Piper Sandler increased their price objective on CVS Health from $72.00 to $74.00 and gave the stock an "overweight" rating in a report on Friday, March 21st. Truist Financial boosted their target price on CVS Health from $82.00 to $84.00 and gave the stock a "buy" rating in a report on Monday, May 12th. Finally, Argus set a $77.00 target price on CVS Health in a research report on Tuesday, February 18th. Two research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $74.75.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.